Alice Park
November 10, 2020

For several years, doctors and patients have been closely following the development of the drug aducanumab, hoping that it might finally be the first medication to stop the cycle of failure that has been the fate of dozens of Alzheimer’s drug candidates that have come before. If approved, it would become the first treatment for Alzheimer’s; current medications address symptoms of the disease but do not tackle the root causes of the neurodegenerative illness. Those hopes were slowly quashed during a seven-hour meeting of a Food and Drug Administration (FDA) advisory committee last week.

Read more: